AI powered and now publicly traded, Exscientia adds $464M to fuel drug R&D

Healthcare

Exscientia’s IPO and private placement raised $464 million to support its artificial intelligence-based approach to discovering and developing new drugs. In addition to partnerships with pharmaceutical companies, an alliance with the Bill & Melinda Gates Foundation is focused on developing antiviral drugs for future pandemics.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.